Orasure Technologies Inc OSUR
We take great care to ensure that the data presented and summarized in this overview for ORASURE TECHNOLOGIES INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding OSUR
View all-
Black Rock Inc. New York, NY7.38MShares$25.5 Million0.0% of portfolio
-
Private Management Group Inc4.42MShares$15.2 Million0.59% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.36MShares$15 Million0.0% of portfolio
-
Neuberger Berman Group LLC New York, NY4.28MShares$14.8 Million0.01% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.82MShares$13.2 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA2.76MShares$9.51 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.57MShares$8.87 Million0.01% of portfolio
-
American Century Companies Inc Kansas City, MO2.51MShares$8.64 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY1.94MShares$6.69 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.76MShares$6.06 Million0.0% of portfolio
Latest Institutional Activity in OSUR
Top Purchases
Top Sells
About OSUR
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company's principal products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands; microbiome collection products; and GenoFIND genomics laboratory services. In addition, the company provides ORAcollect, RNA and OMNIgene, and RAL collection devices for use in connection with COVID-19 molecular testing; offers Colli-Pee collection device for the volumetric collection of first void urine; and manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the academic research and commercial applications, including ancestry, disease risk management, lifestyle, and animal testing. Further, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania.
Insider Transactions at OSUR
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 24
2025
|
John P. Kenny Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,657
+4.33%
|
$19,971
$3.01 P/Share
|
Jun 04
2025
|
Manner Carrie Eglinton President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
193,249
-4.86%
|
$386,498
$2.9 P/Share
|
Jun 04
2025
|
Manner Carrie Eglinton President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
335,710
+14.23%
|
-
|
May 14
2025
|
Mara G. Aspinall Director |
BUY
Grant, award, or other acquisition
|
Direct |
71,017
+28.43%
|
-
|
May 14
2025
|
David Shulkin Director |
BUY
Grant, award, or other acquisition
|
Direct |
71,017
+35.98%
|
-
|
May 14
2025
|
Lelio Marmora Director |
BUY
Grant, award, or other acquisition
|
Direct |
71,017
+35.2%
|
-
|
May 14
2025
|
Robert W. Mc Mahon Director |
BUY
Grant, award, or other acquisition
|
Direct |
71,017
+39.84%
|
-
|
May 14
2025
|
Nancy J Gagliano Director |
BUY
Grant, award, or other acquisition
|
Direct |
71,017
+30.99%
|
-
|
May 14
2025
|
John P. Kenny Director |
BUY
Grant, award, or other acquisition
|
Direct |
71,017
+33.57%
|
-
|
May 13
2025
|
Mara G. Aspinall Director |
SELL
Payment of exercise price or tax liability
|
Direct |
6,666
-5.83%
|
$13,332
$2.65 P/Share
|
May 13
2025
|
David Shulkin Director |
SELL
Payment of exercise price or tax liability
|
Direct |
4,999
-8.29%
|
$9,998
$2.65 P/Share
|
May 13
2025
|
Lelio Marmora Director |
SELL
Payment of exercise price or tax liability
|
Direct |
7,977
-11.78%
|
$15,954
$2.65 P/Share
|
May 13
2025
|
Robert W. Mc Mahon Director |
SELL
Payment of exercise price or tax liability
|
Direct |
6,427
-15.07%
|
$12,854
$2.65 P/Share
|
May 13
2025
|
Nancy J Gagliano Director |
SELL
Payment of exercise price or tax liability
|
Direct |
4,387
-4.79%
|
$8,774
$2.65 P/Share
|
Mar 25
2025
|
John P. Kenny Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,385
-1.95%
|
$4,155
$3.55 P/Share
|
Mar 01
2025
|
Manner Carrie Eglinton President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
62,382
-3.56%
|
$187,146
$3.63 P/Share
|
Mar 01
2025
|
Manner Carrie Eglinton President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
462,414
+20.89%
|
-
|
Mar 01
2025
|
Kenneth J Mc Grath Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
10,673
-2.26%
|
$32,019
$3.63 P/Share
|
Mar 01
2025
|
Kenneth J Mc Grath Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,647
+17.59%
|
-
|
Mar 01
2025
|
Kathleen Gallagher Weber Chief Product Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,312
-2.08%
|
$24,936
$3.63 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 1.53M shares |
---|---|
Open market or private purchase | 239K shares |
Payment of exercise price or tax liability | 357K shares |
---|